CliffBio
small molecule

JATENZO

TESTOSTERONE UNDECANOATE

Loss of exclusivityApril 2039latest FDA-listed patent expiry
CompanyTolmar →View the full company profile on CliffBio

Drug detail

Brand nameJATENZO
Active ingredientTESTOSTERONE UNDECANOATE
Strength237MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalMarch 2019
Marketing statusRX

Listed patents

PatentExpiresType
12605391April 2039use U-1103
11564933April 2039use U-1103
8492369December 2030product
11426416April 2030use U-3420
10617696April 2030substance, product
10543219April 2030use U-2506
11179403April 2030use U-2506
8778916April 2030product
8241664March 2029product
11331325January 2027use U-2506
11179402April 2026substance, product

More from Tolmar

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

JATENZO patent cliff — loss of exclusivity April 2039 | CliffBio